Table 3

Poisson regression for insulin end points associated with thiazolidinediones or sulphonylureas in patients with type 2 diabetes mellitus

	TZDs versus Sulphonylureas
Cohort	Crude rate in TZD group per 100 PYs	Crude rate in SU group per 100 PYs	TZD PYs of follow-up	Crude rate ratio	Adjusted rate difference per 100 PYs (95% CI)
Men, age ≥60	0.54	2.35	734	0.23	−0.80 (−1.51 to −0.08)
Men, age <60	1.73	3.75	1271	0.46	−1.50 (−2.44 to −0.56)
Women, age ≥60	0.76	2.75	656	0.28	−1.18 (−2.05 to −0.32)
Women, age <60	1.94	5.91	977	0.33	−2.22 (−3.46 to −0.99)

	Pioglitazone (PIO) versus sulphonylureas
Cohort	Crude rate in PIO group per 100 PYs	Crude rate in SU group per 100 PYs	PIO PYs of follow-up	Crude rate ratio	Adjusted rate difference per 100 PYs (95% CI)
Men, age ≥60	0.77	2.35	260	0.33	−0.73 (−1.9 to 0.43)
Men, age <60	1.92	3.75	469	0.51	−1.37 (−2.76 to 0.02)
Women, age >=60	0.42	2.75	240	0.15	−1.09 (−2.08 to −0.11)
Women, age <60	2.05	5.91	341	0.35	−2.04 (−3.79 to −0.29)

	Rosiglitazone (ROS) versus slphonylureas
Cohort	Crude rate in ROS group per 100 PYs	Crude rate in SU group per 100 PYs	ROS PYs of follow-up	Crude rate ratio	Adjusted rate difference per 100 PYs (95% CI)
Men, age ≥60	0.42	2.35	474	0.18	−0.81 (−1.57 to −0.06)
Men, age <60	1.62	3.75	802	0.43	−1.52 (−2.59 to −0.45)
Women, age ≥60	0.96	2.75	415	0.35	−1.21 (−2.31 to −0.12)
Women, age <60	1.89	5.91	636	0.32	−2.27 (−3.65 to −0.89)